Algert Global’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Algert Global’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,357	Closed	-$855K	–	1402
2022 Q2	$855K	Sell	11,357 -21,650	-66%	-$962K	0.06%	543
2022 Q1	$886K	Buy	33,007 +28,426	+621%	+$955K	0.06%	577
2021 Q4	$219K	Sell	4,581 -4,990	-52%	-$223K	0.03%	825
2021 Q3	$636K	Buy	9,571 +1,351	+16%	+$96.2K	0.08%	439
2021 Q2	$641K	Buy	+8,220	New	+$607K	0.22%	149

Algert Global's TPTX Position: Q3 2022 in Review

Algert Global sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 11,357 shares — an estimated $855K sold.

Algert Global first reported a position in TPTX in Q2 2021 and held it in 5 quarters. The position peaked at $886K in Q1 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Algert Global reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Algert Global sold 11,357 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $855K.
Algert Global first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Algert Global's Turning Point Therapeutics, Inc. Common Stock position peaked at $886K in Q1 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Algert Global's 13F filing for Q3 2022, filed 15 Nov 2022.